Compare KZIA & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KZIA | UGRO |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.2M | 13.2M |
| IPO Year | 2002 | 2018 |
| Metric | KZIA | UGRO |
|---|---|---|
| Price | $9.50 | $19.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.67 | N/A |
| AVG Volume (30 Days) | 107.0K | ★ 10.8M |
| Earning Date | 11-07-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,008,850.00 |
| Revenue This Year | N/A | $98.41 |
| Revenue Next Year | N/A | $23.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $0.11 |
| 52 Week High | $17.40 | $39.68 |
| Indicator | KZIA | UGRO |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 61.54 |
| Support Level | $5.64 | $0.71 |
| Resistance Level | $10.49 | $39.68 |
| Average True Range (ATR) | 0.75 | 7.35 |
| MACD | 0.06 | 0.61 |
| Stochastic Oscillator | 96.84 | 45.64 |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).